Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.77 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinazoline SCHEMBL28041229 | 0.90 | EGFR (0.62) | EGFRPIK3CDPIK3CAPDGFRBPDGFRA | |
| Quinazoline SCHEMBL29902476 | 0.89 | EGFR (0.77) | EGFRPIK3CDPIK3CAPDGFRBPDGFRA | |
| Quinazoline SCHEMBL5438273 | 0.89 | EGFR (0.77) | EGFRPIK3CDPIK3CAPDGFRBPDGFRA | |
| Quinazoline SCHEMBL27407620 | 0.88 | EGFR (0.91) | EGFRPIK3CDPIK3CAPDGFRBPDGFRA | |
| Quinazoline SCHEMBL29356169 | 0.88 | EGFR (1.00) | EGFRPIK3CDPIK3CAPDGFRBPDGFRA | |
| Quinazoline SCHEMBL29490398 | 0.88 | EGFR (1.00) | EGFRPIK3CDPIK3CAPDGFRBPDGFRA | |
| Quinazoline SCHEMBL22833783 | 0.88 | EGFR (1.00) | EGFRPIK3CDPIK3CAPDGFRBPDGFRA | |
| Quinazoline SCHEMBL5920 | 0.88 | EGFR (1.00) | EGFRPIK3CDPIK3CAPDGFRBPDGFRA | |
| Quinazoline SCHEMBL27762358 | 0.87 | EGFR (0.69) | EGFRPIK3CDPIK3CAPDGFRBPDGFRA | |
| Quinazoline SCHEMBL28109843 | 0.86 | EGFR (0.87) | EGFRPIK3CDPIK3CAPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275643-A1 | AROYLQUINOLINE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275643-A1 | AROYLQUINOLINE COMPOUNDS | TUBA1C, TUBB1, TUBB3 | EGFR 2856/4885PIK3CD 1480/4885PIK3CA 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.